AlphAIalphai — Financial news for AI agents
yahoo.comAUG 155 min read$CELC

Celcuity Q2 Earnings Call Highlights

Celcuity (NASDAQ:CELC) reported Q2 earnings call highlights for its gedatolisib programs. In REVTORPYK, adverse-event discontinuations were 5.2% (mutant cohort) for the triplet and 3.8% for the doublet, versus 19% for alpelisib. The company is expanding VIKTORIA-2 and advancing a prostate Phase Ib/II trial with darolutamide. Q2 net loss was $78.9M ($1.44/share). Cash totaled $754M.

Original reporting
yahoo.com
Published Aug 15, 2026, 6:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 15, 2026, 6:44 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Celcuity Q2 Earnings Call Highlights — source image
Source · yahoo.com
Decision brief

The 30-second read

$CELCNeutralMed
01

Why it matters

Traders can update probabilities around launch execution (expanded-access shipping, second-site FDA clearance timeline) and near-term clinical risk (adverse-event discontinuation rates in mutant vs wild-type cohorts). The Q2 cash position and convertible note proceeds also inform financing overhang into 2029.

02

Market read

The article combines Q2 financials, safety/tolerability discontinuation rates for REVTORPYK, and a concrete late-Q3 manufacturing shipment expectation, which together can move biotech risk pricing.

03

What to watch

SG&A surge for pre-launch and ongoing cash burn could increase financing/dilution risk, partially offsetting the de-risking narrative from manufacturing-site validation and expanded-access shipping.

Relevance 7/10Novelty 6/10Timing: pre-market today, with late-Q3 shipment confidence and Q2 financials driving near-term positioning

Background

Celcuity is preparing commercial launch for REVTORPYK and expanding its first-line breast cancer and prostate cancer programs for gedatolisib-based combinations.

Company-level read

Ticker impact

$CELCNeutralMedium confidence
Context

Celcuity disclosed Q2 results plus REVTORPYK adverse-event discontinuation rates and plans to ship late Q3 after FDA clearance for a second manufacturing site.

Expected impact

Moderate upside bias if investors view discontinuation rates and late-Q3 shipping confidence as de-risking launch; downside risk if cash burn and SG&A ramp raise dilution concerns.

Evidence & confidence

The article adds multiple decision-relevant datapoints (trial discontinuation rates, expanded-access shipping, and manufacturing-site clearance timeline) but does not provide a new efficacy endpoint or explicit guidance that would likely dominate valuation immediately.

Market effects

Sector

Highlights how safety tolerability and manufacturing readiness can become key trading drivers for precision oncology launches.

Regional

Primarily US biotech sentiment, with no direct regional macro linkage.

Global

Limited global spillover beyond oncology peers watching similar PI3K/targeted-therapy tolerability and supply timelines.

Counterpoint

What could challenge this read

Discontinuation due to adverse events may not translate into durable efficacy or regulatory/label confidence; investors may discount safety-only signals without mature PFS/response.

Key entities

  • company
    Celcuity

    Clinical-stage precision oncology company developing gedatolisib programs and preparing REVTORPYK launch.

  • program
    REVTORPYK

    Second-line breast cancer program with reported adverse-event discontinuation rates and launch preparation details.

  • program
    VIKTORIA-2

    First-line breast cancer expansion evaluating gedatolisib combinations in endocrine-sensitive and endocrine-resistant settings.

  • drug
    gedatolisib

    Targeted oncology agent used in multiple combination trials discussed in the call.

  • regulator
    FDA

    Second manufacturing site requires FDA clearance before shipments can begin.

Read at source← All news

Related articles

SEP 1
$CELCHighAI 8/10

How Investors May Respond To Celcuity (CELC) sNDA For REVTORPYK In PIK3CA-Mutant Breast Cancer

Celcuity Inc. (CELC) submitted an sNDA for REVTORPYK (gedatolisib) to treat HR+/HER2- advanced breast cancer with PIK3CA mutations, based on positive Phase 3 trial data. If approved, it would be the first therapy targeting all class I PI3K isoforms and both mTOR complexes. The company projects $817.9M revenue and $267.5M earnings by 2029, up from current losses. The sNDA builds on the July 2026 approval for non-mutant cases, potentially expanding market reach.

simplywall.st2 min
AUG 30
$CELCMedAI 8/10

What Could Celcuity (CELC) Gain If The FDA Clears REVTORPYK For Breast Cancer?

Celcuity (CELC) submitted a supplemental New Drug Application to the FDA for REVTORPYK to treat advanced breast cancer with PIK3CA mutations. The filing is supported by Phase 3 trial results showing improved progression-free survival. If approved, REVTORPYK could become the first therapy for this indication, potentially expanding Celcuity's market. Management estimates a US$5b to US$6b addressable market and potential peak revenue of US$2.5b to US$3b for gedatolisib in this setting.

simplywall.st2 min
AUG 26
$CELCMedAI 8/10

Celcuity Submits SNDA To FDA For REVTORPYK In Advanced Breast Cancer

Celcuity Inc. (CELC) submitted a supplemental New Drug Application to the FDA for REVTORPYK, an investigational therapy for advanced breast cancer with a PIK3CA mutation. The application is supported by Phase 3 trial data showing significant improvements in progression-free survival and response rates. If approved, REVTORPYK would be the first therapy of its kind for this patient population. CELC stock closed at $92.27, up 1.63%.

rttnews.com1 min
AUG 24
$CELCLow

How Investors May Respond To Celcuity (CELC) Deepening Losses As Gedatolisib Commercial Plans Advance

Celcuity Inc. (CELC) reported a net loss of $78.86 million in Q2 2026, with first-half losses widening to $131.71 million. The company is advancing gedatolisib and preparing for commercialization, with FDA approval of REVTORPYK in July. Investors focus on whether REVTORPYK revenue can offset increased cash burn. Celcuity projects $817.9 million revenue and $267.5 million earnings by 2029, implying a 77% upside from current prices.

simplywall.st3 min
AUG 20
$CELCMed

Celcuity (CELC) Q2 2026 Earnings Call Transcript

Celcuity (CELC) reported Q2 2026 net loss of $78.9M ($1.44/ share), up from $45.3M last year. Cash reserves total $754M, with $557.2M raised from a convertible note offering. The company launched Revtopik, a drug for advanced breast cancer, and plans a supplemental New Drug Application. Clinical trials showed significant reduction in disease progression risk. Management expects cash to fund operations into 2029.

fool.com3 min